Dear Authors,
If you believe that your paper was mistakenly rejected by other leading journals and you do not agree with final decision, the editors of Reports of Practical Oncology and Radiotherapy offer new fast track review. You may submit your manuscript to Reports of Practical Oncology and Radiotherapy together with all prior peer-reviews obtained from the other journal and your rebuttal letter. We guarantee review based decision within 72 hours from the time we will receive your manuscript.

Fast track submission process: Please submit the manuscript with all reviews and rebuttal letter by email to Dr. Michal Masternak (michal.masternak@ucf.edu) for fast review processing. To assure immediate attention the email title must to include: RPOR-fast track- Last Name First Name (of corresponding author).

Volume 9, Number 5, 2004

Clinical value of molecular changes in ovarian carcinoma

Jolanta Kupryjańczyk

Summary:

Studies carried out on cell lines and ovarian cancer xenografts have indicated that some disturbances of the expression of some groups of genes in cancer cells have a role in the efficacy of chemotherapy, including the response to given groups of drugs. Cisplatin is a DNA-damaging agent. On the basis of the data obtained from cell lines the level of the expression of TP53, BCL and BAX proteins affects the response of the ovarian cancer to cisplatin, however this effect has not been confirmed in clinical studies. In the last few years, in the framework of a multicentre project, we have investigated a group of 233 patients with ovarian cancer treated with cisplatin regimen (cisplatin plus cyclophosphamide). We have shown that ovarian carcinomas with TP53 protein accumulation (TP53+) and those without accumulation (TP53-) constitute
separate biological groups. In our studies the TP53 status had an impact on the clinical value of other proteins such as BAX and BCL-2, as well as of some clinical factors, eg. residual tumor size or clinical stage. BCL-2 expression had a negative influence on complete remission only in the TP53(-) group. On the other hand, the risk of a relapse was lower for the higher BAX expression in the TP53 (+) group. Now we have embarked on similar studies on a group of patients treated with taxanes. In the future, the evaluation of molecular markers may provide a basis for a more individualised chemotherapy of ovarian cancer patients.

Signature: Rep Pract Oncol Radiother, 2004; 9(5) : 149-155

FULL TXT (PDF: 0,12MB)

« back

 
INDEXED IN:

Indexed in: EMBASE®, the Excerpta Medica database, the Elsevier BIOBASE (Current Awareness in Biological Sciences) and in the Index Copernicus.

http://www.sciencedirect.com/science/journal/15071367/19/2